Bicycle Therapeutics BCYC
NASDAQ BCYC
$4.30 +0.06 (+1.42%)
At close: Sep 4, 2026 · 4:00 PM EDT

Bicycle Therapeutics (BCYC) Long-Term Debt Issuances (2021)

Bicycle Therapeutics' (BCYC) quarterly Long-Term Debt Issuances came in at $15.0 million in Q1 2021.

Analysis

Bicycle Therapeutics (BCYC) Long-Term Debt Issuances (2021) Analysis & Trends

Bicycle Therapeutics (BCYC) has 1 years of Long-Term Debt Issuances data on file, last reported at $15.0 million in Q1 2021.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $15.0 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $15.0 million (changed N/A YoY) and the FY2021 annual result came in at $15.0 million, changed 0.0% from the prior year.
  • Long-Term Debt Issuances steadied at $15.0 million in Q1 2021.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $15.0 million in Q1 2021 to a low of $15.0 million in Q1 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Bicycle Therapeutics 299.81 Mn 299.81 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 15.00 Mn